Journal article
ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly
SA Ward, P Raniga, NJ Ferris, RL Woods, E Storey, MJ Bailey, A Brodtmann, PA Yates, GA Donnan, RE Trevaks, R Wolfe, GF Egan, JJ McNeil
International Journal of Stroke | SAGE PUBLICATIONS LTD | Published : 2017
Abstract
Rationale: Cerebral microbleeds seen on brain magnetic resonance imaging are markers of small vessel disease, linked to cognitive dysfunction and increased ischemic and hemorrhagic stroke risk. Observational studies suggest that aspirin use may induce cerebral microbleeds, and associated overt intracranial hemorrhage, but this has not been definitively resolved. Aims: ASPREE-NEURO will determine the effect of aspirin on cerebral microbleed development over three years in healthy adults aged 70 years and over, participating in the larger ‘ASPirin in Reducing Events in the Elderly (ASPREE)’ primary prevention study of aspirin. Sample size: Five hundred and fifty-nine participants provide 75% p..
View full abstractGrants
Awarded by National Institute on Aging
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The ASPREE study has been funded principally by the National Institute on Aging (grant number 1RO1AG029824-01A2), the Australian National Health and Medical Research Council (NHMRC) (grant number 334047), Monash University and the Victorian Cancer Agency. ASPREE-NEURO has funding from the NHMRC (grant number 1086188), and support from Monash Biomedical Imaging.